```
<!--StartFragment-->
RESULT 14
AAW62772
    AAW62772 standard; protein; 303 AA.
ID
XX
AC
    AAW62772:
XX
DT
     23-SEP-1998 (first entry)
XX
DE
    Human immunoglobulin receptor designated FDF03.
XX
KW
    Human; type I transmembrane protein; immunoglobulin-like domain; FDF03;
     activated monocyte; YE01; KTE03; control; development; differentiation;
KW
KW
    mammalian immune system; treatment; cancerous condition;
KW
    degenerative condition; autoimmune response; transplantation rejection;
KW
    graft versus host disease; inflammatory condition; detection; diagnosis;
KW
    drug screening.
XX
os
    Homo sapiens.
XX
PN
    WO9824906-A2.
XX
PD
    11-JUN-1998.
XX
PF
    05-DEC-1997;
                   97WO-US021101.
XX
PR
    06-DEC-1996; 96US-0032252P.
PR
    09-DEC-1996; 96US-00762187.
PR
    16-DEC-1996; 96US-0033181P.
PR
    21-MAR-1997; 97US-0041279P.
XX
PA
    (SCHE ) SCHERING CORP.
XX
PΙ
    Adema GJ, Meyaard L, Gorman DM, Mcclanahan TK, Zurawski SM;
PΙ
     Zurawski G, Lanier LL, Phillips JH;
XX
DR
    WPI: 1998-333325/29.
DR
    N-PSDB; AAV38987.
XX
PT
    New isolated activated monocyte cell gene(s) - used to develop products
PΤ
     for treating e.g. cancer, degenerative conditions, autoimmune responses,
PT
    transplant rejection or inflammatory conditions.
XX
PS
    Claim 1; Page 60-61; 104pp; English.
XX
CC
    The present sequence represents a human protein, FDF03, which is a type I
CC
     transmembrane protein comprising an extracellular portion characterised
CC
     by immunoglobulin-like domains, indicating that the protein is a receptor
CC
    member of the immunoglobulin superfamily. The FDF03 gene is found in
    activated monocytes. The specification also describes other proteins
CC
    encoded by activated monocytes, which are designated YEO1 and KTEO3. The
    genes function in controlling development, differentiation, and/or
CC
CC
    physiology of the mammalian immune system. The products can be used for
CC
    treating abnormal proliferation, regeneration, degeneration or atrophy.
CC
    They can be used for treating e.g. cancerous conditions, degenerative
CC
    conditions, autoimmune responses, transplantation rejection, graft versus
CC
    host disease, or inflammatory conditions. The products can also be used
CC
    for detection, diagnosis and drug screening
XX
SO
    Sequence 303 AA;
```

Query Match	80.4%; Score 958; DB 2; Length 303; Similarity 80.8%; Pred. No. 3.6e-76;
	5; Conservative 15; Mismatches 19; Indels 10; Gaps 2;
Qy 1	MGRPLLLPLLLLQPPAFLQPGGSTGSGPSYLYGVTQPKHLSASMGGSVEIPFSFYYPWE 60
Db 1	MGRPLLLPLLPLLPPAFLQPSGSTGSGPSYLYGVTQPKHLSASMGGSVEIPFSFYYPWE 60
Qy 61	LAIVPNVRISWRRGHFHGQSFYSTRPPSIHKDYVNRLFLNWTEGQESGFLRISNLRKEDQ 120
Db 61	LATAPDVRISWRRGHFHGQSFYSTRPPSIHKDYVNRLFLNWTEGQKSGFLRISNLQKQDQ 120
Qy 121	SVYFCRVELDTRRSGRQQLQSIKGTKLTITQAVTTTTTWRPSSTTTIAGLRV 172
Db 121	SVYFCRVELDTRSSGRQQWQSIEGTKLSITQAVTTTTQRPSSMTTTWRLSSTTTTTGLRV 180
Qy 173	TESKGHSESWHLSLDTAIRVALAVAVLKTVILGLLCLLLLWWRRRKGSR 221
Db 181	: : : : : : :

<!--EndFragment-->